Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
Loading... 
Loading...